Aman Mehta: Taking Torrent Pharma Into Its Next Era

From strengthening India's chronic-therapy leadership to integrating major acquisitions and shaping a broader growth agenda, Aman Mehta is emerging as one of the key next-generation leaders in Indian pharmaceuticals.

Aman Mehta · Managing Director · Torrent Pharmaceuticals
The Cover Story editorial team · 14 September 2026

India's pharmaceutical industry is entering a more demanding phase.

The next decade will not be defined only by manufacturing scale or generic-drug exports. It will increasingly be shaped by differentiated brands, chronic therapies, complex markets, disciplined acquisitions, research capability and the ability to create healthcare businesses that can compete globally.

That is the environment Aman Mehta now steps into as Managing Director of Torrent Pharmaceuticals.

His appointment, for five years effective 1 August 2025, marked an important moment in the evolution of one of India's most established pharmaceutical companies. It also placed him at the centre of a business that has become substantially larger, more diversified and more strategically ambitious.

For Mehta, the challenge is clear: take a strong pharmaceutical institution and make it stronger for the next generation.

Leadership Built From Inside the Business

Mehta’s rise within Torrent has not been sudden.

The third generation of the Torrent Group’s founding Mehta family and the son of chairman Samir Mehta, he joined the group in 2013 and has spent more than a decade across its businesses, working in both power and pharmaceuticals before assuming increasingly important responsibilities within Torrent Pharma.

A graduate in economics from Boston University with an MBA from Columbia University, he brought a combination of international education and operating exposure inside the family enterprise.

In August 2022, he was appointed a whole-time director of Torrent Pharma.

His responsibilities subsequently expanded across the company’s India and Rest of World businesses, with particular emphasis on strategy, acquisitions, new product launches and market expansion.

That progression matters.

Next-generation leadership inside a large group is often discussed in terms of succession. A more useful test is whether responsibility expands alongside measurable business contribution.

In Mehta’s case, much of that contribution has been visible in India — the company’s largest and strategically most important market.

Strengthening the India Business

Torrent Pharma has built one of the strongest chronic-therapy franchises in Indian pharmaceuticals.

Its leadership spans categories including cardiovascular medicine, central nervous system treatments, gastroenterology, women’s healthcare, vitamins and minerals, and cosmo-dermatology.

These categories are particularly important because chronic therapies typically create deeper relationships between doctors, patients and pharmaceutical brands than short-duration treatments.

Under Mehta’s leadership, the India business has continued to expand through a combination of organic growth, product launches and acquisitions.

The company has consistently emphasised market-share gains in its focus therapies, while its portfolio includes a significant number of brands with substantial annual sales.

That depth creates a powerful platform.

In pharmaceuticals, scale is useful. But brand strength inside therapeutic categories is often even more valuable.

Torrent’s ability to build doctor confidence and maintain repeat prescription behaviour provides the company with an advantage that cannot be recreated quickly.

Mehta’s challenge is to extend that strength without allowing the portfolio to become complacent.

Acquisitions as a Growth Engine

One of the defining elements of Mehta’s emerging leadership profile has been his role in acquisitions.

Torrent Pharma’s acquisition strategy has been focused not simply on adding revenue, but on expanding brands, therapeutic depth and market reach.

The integration of Unichem became an important proof point. Torrent has credited Mehta with a central role in successfully integrating that acquisition and converting it into long-term value.

The company subsequently continued to pursue inorganic growth.

On 21 January 2026, Torrent became the promoter of JB Chemicals & Pharmaceuticals, acquiring a controlling 46.39 per cent stake as part of a deal valued at around ₹19,500 crore — one of the most significant transactions in India’s recent pharmaceutical consolidation cycle.

That acquisition materially expands Torrent’s branded domestic portfolio, strengthens its position in key therapeutic segments and is expected to lift it from seventh to fifth largest in the Indian pharmaceutical market.

It also raises the complexity of Mehta’s leadership role.

Buying a company is financial. Integrating one is operational.

The difficult work comes afterward: brands, people, distribution, systems, culture and capital all need to be aligned without disrupting the performance that made the target attractive in the first place.

For Mehta, this ability to integrate acquisitions could become one of the most important measures of his tenure.

A Company Becoming Larger

For the year to March 2026, Torrent Pharma reported revenue of approximately ₹13,980 crore, up 21 per cent, with JB Chemicals consolidated from January. Its India and Brazil branded businesses both delivered double-digit growth.

India remains its largest market, while Torrent also has significant positions in markets such as Brazil and Germany, with operations spanning more than 50 countries.

This geographic mix gives the business resilience. But it also creates a more complicated management challenge.

Indian pharmaceuticals increasingly require leaders capable of understanding very different commercial environments at once.

India is brand- and prescription-driven. European markets can be tender-heavy and highly regulated. Brazil has its own pricing, competitive and distribution dynamics. The United States remains strategically important but commercially demanding.

As Managing Director, Mehta is therefore moving beyond one market. His task is increasingly to connect multiple businesses into one coherent growth strategy.

The Next Phase: From Scale to Quality of Growth

Pharma companies are often judged on revenue. The better measure is usually the quality of that revenue.

How much comes from differentiated brands? How defensible are the therapeutic positions? How strong is the pipeline? How disciplined is acquisition spending? How sustainable are margins? How much future growth depends on one geography?

Torrent's current evolution suggests a company increasingly focused on those questions.

Its leadership in chronic therapies gives it a relatively attractive domestic business. Its international presence provides diversification. Its acquisition strategy offers another avenue for growth.

But bigger portfolios create bigger expectations.

Mehta's responsibility is to ensure that growth does not become complexity for its own sake.

The strongest pharmaceutical businesses are rarely the ones with the largest number of products. They are the ones that know where they can win.

Innovation Beyond the Laboratory

Innovation in pharmaceuticals is often interpreted purely as drug discovery.

For Indian companies, innovation can also mean something broader: stronger therapy portfolios, better manufacturing, more intelligent use of data, faster launches, new go-to-market models, efficient integration of acquisitions and deeper medical engagement.

Torrent has historically built its reputation around niche marketing and focused therapeutic segments.

Mehta's opportunity is to update that philosophy for a much more digital and competitive healthcare environment.

Technology will increasingly influence how pharmaceutical companies understand markets, engage physicians, manage supply chains and allocate resources.

The future leader of a pharmaceutical company therefore has to think simultaneously like a healthcare executive, capital allocator and technology adopter.

That combination could define Mehta's next phase.

Building Leadership Credibility

Family-enterprise leaders face a particular challenge.

Their appointment will always attract attention. Their performance determines whether that attention becomes credibility.

Mehta's advantage is that his responsibilities have expanded alongside operating results and increasingly important strategic assignments.

The India business has strengthened. Unichem was integrated. JB Chemicals now represents a much larger test. And he has moved from whole-time director into the Managing Director role.

The appointment reflects both succession planning and a broader transfer of operational responsibility.

That distinction matters.

The strongest next-generation leaders do not simply take over titles. They gradually take over problems.

Mehta now has some of Torrent Pharma's biggest ones.

The Cover Story View

Aman Mehta represents a transition happening across some of India's most important family-led businesses.

The next generation is inheriting companies that are already large, sophisticated and globally connected. That makes leadership harder, not easier.

There is less room for obvious growth. More capital is at stake. Competition is stronger. Governance expectations are higher. And every major acquisition or strategic shift is judged more quickly.

Mehta's opportunity is therefore not simply to preserve Torrent Pharma's position. It is to sharpen it.

The foundations are strong: leading domestic brands, deep chronic-therapy positions, international reach and growing scale.

What comes next will depend on how effectively he integrates acquisitions, protects Torrent's culture, prioritises the right markets and turns size into durable competitive advantage.

If he succeeds, his tenure may ultimately be defined not by succession. It may be defined by transformation — from a successful Indian pharmaceutical company into an even more formidable global healthcare business.

> **"The strongest next-generation leaders do not simply take over titles. They gradually take over problems."**